Enlivex (ENLV) Interest Coverage Ratio Growth (1y) (2016 - 2025)
Enlivex (ENLV) Interest Coverage Ratio Growth (1y) (2016 - 2025) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -60.78% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -25.59% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,170.12% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 751.68% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.48% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -53.46% |
| 10 | Enlivex | 4.51 Mn | -1.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.57% |
| Sep 30, 2025 | -10.22% |
| Jun 30, 2025 | -73.64% |
| Mar 31, 2025 | -19.53% |
| Dec 31, 2024 | 228.48% |
| Sep 30, 2024 | -148.71% |
| Jun 30, 2024 | -110.88% |
| Mar 31, 2024 | 44.99% |
| Dec 31, 2023 | 64.96% |
| Sep 30, 2023 | 121.37% |
| Jun 30, 2023 | 2,551.97% |
| Mar 31, 2023 | 98.40% |
| Dec 31, 2022 | 35.24% |
| Sep 30, 2022 | -107.59% |
| Jun 30, 2022 | 99.50% |
| Mar 31, 2022 | -1,006.88% |
| Dec 31, 2021 | -1,291.16% |
| Sep 30, 2021 | 3,898.66% |
| Jun 30, 2021 | -9,660.50% |
| Mar 31, 2021 | -83.09% |